Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00461812
Status:
TERMINATED
Last Update Posted:
2017-09-20
First Post:
2007-04-16
Brief Title:
A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma
Sponsor:
Johns Hopkins University
Organization:
Johns Hopkins University
Study Overview
Official Title:
A Single-Blind Randomized Positive-controlled Study to Compare Monotherapy With an Inhaled Corticosteroid Mometasone to Combination Therapy With an Inhaled Corticosteroid a Long-Acting Bronchodilator Advair in Patients With Milder Persistent Asthma
Status:
TERMINATED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
by sponsor due to failure to recruit patients who had mild persistent asthma who were not already on Advair 25050 or 50050
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The research hypothesis for the proposed study asks the question can Asmanex demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product Advair in control of mild persistent asthma
The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid Asmanex is comparable to combination therapy with Advair 10050 when measured by this standard methodology methacholine bronchoprovocation in subjects with mild persistent asthma
The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid Asmanex is comparable to combination therapy with Advair 10050 when measured by this standard methodology methacholine bronchoprovocation in subjects with mild persistent asthma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None